Medical Oncology

, 31:859

miR-200b as a prognostic factor targets multiple members of RAB family in glioma

  • Qing Liu
  • Hailin Tang
  • Xiaoping Liu
  • Yiwei Liao
  • Haoyu Li
  • Zijin Zhao
  • Xianrui Yuan
  • Weixi Jiang
Original Paper

DOI: 10.1007/s12032-014-0859-x

Cite this article as:
Liu, Q., Tang, H., Liu, X. et al. Med Oncol (2014) 31: 859. doi:10.1007/s12032-014-0859-x

Abstract

miR-200b is a tumor suppressor in multiple tumors including gastric cancer, breast cancer, ovarian cancer and glioma. In this study, we detected the expression of miR-200b and analyzed its correlation with clinicopathological parameters in glioma tissues. miR-200b was downregulated in glioma tissues. And its downexpression was correlated with poor prognosis in gliomas. Members of RAB family, RAB21, RAB23, RAB18 and RAB3B were predicted to be novel targets of miR-200b. The direct suppression of RAB21, RAB23, RAB18 and RAB3B expressions by miR-200b was revealed by luciferase reporter assay, quantitative RT-PCR analysis and Western blot. Furthermore, the overall survival of patients with different expression of RABs was analyzed. The expression of RAB21, RAB23, RAB18 and RAB3B was related to the prognosis and histopathology of glioma. The patients who had the upregulation of all the four RABs had the worst outcome; those who had the downregulation of all RABs had the best outcome (p < 0.001). miR-200b was a potential biomarker for glioma prognosis.

Keywords

miR-200b RAB family Glioma Prognosis 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Qing Liu
    • 1
    • 2
  • Hailin Tang
    • 3
  • Xiaoping Liu
    • 3
  • Yiwei Liao
    • 1
    • 2
  • Haoyu Li
    • 1
    • 2
  • Zijin Zhao
    • 1
    • 2
  • Xianrui Yuan
    • 1
    • 2
  • Weixi Jiang
    • 1
    • 2
  1. 1.Department of Neurosurgery, Xiangya HospitalCentral South UniversityChangshaPeople’s Republic of China
  2. 2.The Institute of Skull Base Surgery and Neurooncology at Hunan, The Neurosurgical Institute of Central South UniversityChangshaPeople’s Republic of China
  3. 3.Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouPeople’s Republic of China

Personalised recommendations